Respiratory diseases
Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterized by an airflow reduction in the respiratory flow and impaired...
Neonatology
Physiological delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
Rare diseases
The term “rare” applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by the legislation of each individual country. The EU sets this threshold at 0.05% of the population, i.e. one case for every 2,000...
Special care
Chiesi is also focusing its attention on the treatment and care of patients suffering from chronic severe conditions treated primarily by specialists in the hospital setting, which can be potentially life threatening: Cystic Fibrosis and Solid Organ Transplantation. Thanks to our...
History
The history of the Chiesi company is the history of a personal dream that became collective: “To create innovative tools with which to provide effective treatment”.
For more information - Chiesi Group and Chiesi Central Eastern Europe (Chiesi Pharmaceuticals...
Chiesi Bulgaria
Chiesi Bulgaria is a part of an international Group focusing on research, which develops and offers innovative pharmaceutical solutions of added value aimed at improving patients' quality of life.
We have always adhered to a series of corporate values in the pursuit of our company...
Code of ethics, compliance and disclosure
Ethics & Compliance / Code of Ethics & Compliance
The Code of Ethics and Compliance expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical...
Patient organisations
List of Patient Organizations supported by Chiesi Bulgaria
in 2015:
Association “Organization of Thalassemia Patients in Bulgaria”
Partial support of the Organization of Thalassemia Patients in Bulgaria (OTPB) in conducting activities on the occasion of the...
Working at Chiesi
Job opportunities
Chiesi is continually looking for new talent for opportunities in all areas of the organization. Explore our global career portal and register to receive updates and current job openings.
Visit our global career portal here: careers.chiesi.com.
Click...
Contacts
The following contact details must to be used for comments or questions concerning our Company and cannot be used to report adverse event to our products or for medical questions. For this kind of reporting, please refer to PHARMACOVIGILANCE
Legal information
Company name: Chiesi Bulgaria Ltd.
Managing Director: MD Andrey Nikolaev Kenderov
Principal office: 83 Gyueshevo Str., Business Centre Serdika, Ofiice 104, 1330 Sofia, Bulgaria
Co. Reg. No:...
Disclaimer
Chiesi Bulgaria Ltd. has prepared the information contained on this website from various internal and external sources with due professional care. All information on this webpage is intended for health care professionals and contacts. For more information get in touch with our team.
Please...
Pharmacovigilance
Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to patient safety and the risk-benefit ratio of our products...
DATA PRIVACY
This policy provides information regarding the use of cookies and other similar technologies on the website www.chiesi.at (hereinafter referred to as the "Website"). This notice is provided to the user in compliance with European legislation on the processing of personal data and electronic...
Chiesi Guidelines
Ethics & Compliance / Code of Ethics & Compliance
The Code of Ethics and Compliance expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical...
Disclosure
EFPIA
As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) and ARPharM (The Association of the Research-based Pharmaceutical Manufacturer in Bulgaria) we are fostering the transparency on the interaction between the pharmaceutical industry and health care...
Credits
This project was edited and produced by Dynamic Mind.
B Corp and Benefit Society
Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the heart...
Our approach
Sustainability has always been a primary concern in the way Chiesi operates and has increasingly become a focus with a view to shared value. Today, it represents a crucial element of the strategic vision of the company, which is committed to:
adopting a governancesystem based on...
We ACT - Sustainability Manifesto
We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make progress.
At...
Supply Chain Sustainability
Code of Interdependence
As a certified B Corp company, the Chiesi Group introduced the new Chiesi "Code of Interdependence" in February 2020. This is a Suppliers Code of Conduct for strategic suppliers of the Group and forms the basis for future relationships with our...
Ethics and Transparency
The Code of Ethics and Conduct expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical nature.
The application of the following principles is guaranteed by...
Code of Interdependence
As a certified B Corp company, the Chiesi Group introduced the new Chiesi "Code of Interdependence" in February 2020. This is a Suppliers Code of Conduct for strategic suppliers of the Group and forms the basis for future relationships with our suppliers.
The Code of Interdependence is the...
Mission and values
Our Mission as a part of Chiesi Group is to be recognised - research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
Our wish is to maintain a high quality entrepreneurial team characterised by...
Privacy-SpeakUp&BeHeard
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...
Privacy
PRIVACY NOTICE - Website Under Article 13 of Regulation (EU) 2016/679 on the protection of individuals regarding the processing of personal data (hereinafter "GDPR")
This is a privacy notice provided by Chiesi Bulgaria EOOD ("Chiesi"), in accordance with the provisions of European Regulation No....
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
The Group commits €3 million for donations to support the ongoing emergency in Italy
Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world
Company also announces a €1 million investment in...
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases
Company to light up offices around the world including Italy, the United States, and Canada
BOSTON, Mass. - February 26,...
Chiesi Group: performance is up in 2020
Parma (Italy), March 9, 2021 – Growth continues at Chiesi, an international research-focussed pharmaceutical group based in Parma, Italy with 30 affiliates worldwide. The company’s turnover, which stood at €2 billion 229 million in 2020 with an increase of 11.8% compared to 2019,...
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an...
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business
Patients’ experiences and perception of Chiesi at the heart of the new corporate identity
Parma (Italy), March 22, 2021 – Chiesi, the...
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Ensuring continuing medical treatment for patients has been top priority during Covid-19 pandemic.
Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%).
All the company’s 2020 activities, data and...
RARE IS NOT SO RARE: #WEWEARSTRIPES CAMPAIGN 2022 LAUNCHED TO MARK RARE DISEASE DAY
A new initiative launched by professional basketball player Luigi Datome, world-renowned tennis player Elina Svitolina, paralympic swimmer Jessica Long and paralympic athlete Veronica Yoko Plebani shows support for those impacted by rare diseases.
Anyone can join in - each picture posted with...
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
Chiesi Group has been named on Carbon Disclosure Project’s Climate Change A List for its commitment to climate action and transparency.
The Group has also received from Cerved Rating Agency the AA ESG rating with an overall score of 75.1 out of 100.
According to the independent rating...
Alessandro Chiesi appointed Chair of the Chiesi Group, Maria Paola Chiesi becomes the Vice Chair
Alessandro Chiesi has held the post of Chief Commercial Officer since 2020, and succeeds Alberto Chiesi, who, together with his brother Paolo, led the Group to global expansion over the past five decades.
Parma (Italy), July 7th, 2023 – Chiesi announces the appointment...
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.
Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...
Chiesi Group 2023 Financial Results
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
Highlights from Chiesi Group’s 2023 financial report:
Sales increased to over €3 billion, up 10% compared to 2022...
